



January 25, 2022

RE: Use of BD Triplex

To Whom It May Concern,

This letter is to inform you that PMG made a change in the rapid antigen test being used to identify COVID-19 which included a test for influenza A and B. This change was necessary due to the national shortage of BD Veritor rapid antigen tests, a 3-fold increase in demand for COVID-19 tests due to the Omicron variant, as well as manufacturer's production lines shutting down due to labor shortages. In New Mexico's "test to stay" program, our testing requirement went from approximately 5,000 tests per week to over 14,500 per week in less than 10 days, and supply could not keep up with demand.

To respond to the urgent and immediate need for COVID-19 test, and to avoid interruption in the New Mexico K-12 school testing program, PMG was authorized to secure the BD Triplex rapid antigen test which had no anticipated shortage, was immediately available for shipping, and utilized the same testing machines in use throughout the state. The BD Triplex test, like the BD Veritor COVID-19 test, needs only one swab to collect the sample to test for COVID-19 and influenza A and B viruses. PMG will continue to use the BD Triplex until supply of the BD Veritor is sufficient. Due to this change, we have revised our consent form and we will need you to review and sign again as the original consent form did not include the influenza test component.

We also want to acknowledge and let you know that during this transition, PMG's electronic reporting system was not transmitting results from lab-based PCR testing to individuals who were tested. This electronic reporting process has been fixed and we anticipate no future issues.

We greatly appreciate your continued understanding as we all work through the challenges during this pandemic.

Sincerely,

A handwritten signature in black ink, appearing to read "Scott J. Miscovich".

Scott J. Miscovich, MD

President, Founder and CEO